» Articles » PMID: 25960863

Importance of Classical Morphology in the Diagnosis of Myelodysplastic Syndrome

Overview
Date 2015 May 12
PMID 25960863
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by dysplastic, ineffective, clonal and neoplastic hematopoiesis. MDS represent a complex hematological problem: differences in disease presentation, progression and outcome have necessitated the use of classification systems to improve diagnosis, prognostication, and treatment selection. However, since a single biological or genetic reliable diagnostic marker has not yet been discovered for MDS, quantitative and qualitative dysplastic morphological alterations of bone marrow precursors and peripheral blood cells are still fundamental for diagnostic classification. In this paper, World Health Organization (WHO) classification refinements and current minimal diagnostic criteria proposed by expert panels are highlighted, and related problematic issues are discussed. The recommendations should facilitate diagnostic and prognostic evaluations in MDS and selection of patients for new effective targeted therapies. Although, in the future, morphology should be supplemented with new molecular techniques, the morphological approach, at least for the moment, is still the cornerstone for the diagnosis and classification of these disorders.

Citing Articles

MDS-Type Morphologic Abnormalities of Peripheral Blood Granulocytes in Symptomatic COVID-19 Patients.

Sharifi M, Gheibi N, Panahi F, Sharifzadeh S, Nasiri N Int J Hematol Oncol Stem Cell Res. 2024; 18(3):249-253.

PMID: 39257703 PMC: 11381661. DOI: 10.18502/ijhoscr.v18i3.16105.


Tuberculosis-induced aplastic crisis and atypical lymphocyte expansion in advanced myelodysplastic syndrome: A case report and review of literature.

Sun X, Yang X, Xu J, Xiu N, Ju B, Zhao X World J Clin Cases. 2023; 11(19):4713-4722.

PMID: 37469724 PMC: 10353497. DOI: 10.12998/wjcc.v11.i19.4713.


Myelodysplastic syndromes.

Li H, Hu F, Gale R, Sekeres M, Liang Y Nat Rev Dis Primers. 2022; 8(1):74.

PMID: 36396662 DOI: 10.1038/s41572-022-00402-5.


Deep learning application of the discrimination of bone marrow aspiration cells in patients with myelodysplastic syndromes.

Lee N, Jeong S, Park M, Song W Sci Rep. 2022; 12(1):18677.

PMID: 36333407 PMC: 9636228. DOI: 10.1038/s41598-022-21887-w.


De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences.

Leone G, Fabiani E, Voso M Mediterr J Hematol Infect Dis. 2022; 14(1):e2022030.

PMID: 35615324 PMC: 9083943. DOI: 10.4084/MJHID.2022.030.


References
1.
Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

2.
Lambertenghi-Deliliers G, Annaloro C, Oriani A, Soligo D . Myelodysplastic syndrome associated with bone marrow fibrosis. Leuk Lymphoma. 1992; 8(1-2):51-5. DOI: 10.3109/10428199209049817. View

3.
Goasguen J, Bennett J . Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol. 1992; 19(1):4-13. View

4.
Yamazaki H, Nakao S . Border between aplastic anemia and myelodysplastic syndrome. Int J Hematol. 2013; 97(5):558-63. DOI: 10.1007/s12185-013-1324-x. View

5.
Valent P, Horny H . Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009; 39(7):548-53. DOI: 10.1111/j.1365-2362.2009.02151.x. View